TAT-BH4 Peptide Modulates Astrocyte Calcium to Treat ALS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Amyotrophic Lateral Sclerosis (ALS) progression is associated with degeneration of astrocytes, which disrupts the microenvironment essential for motor neuron function, and existing treatments fail to effectively address the underlying astrocyte degeneration and its impact on neuronal health.
Innovation Solution
Administration of the TAT-BH4 peptide, which comprises the BH4 domain of Bcl-XL and the protein transduction domain of the HIV TAT protein, to modulate intracellular calcium signaling and protect astrocytes from degeneration, thereby preventing or slowing ALS progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for ALS, then general symptomatic relief may be achieved, but astrocyte degeneration and its impact on neuronal health are not effectively addressed
Solution Approach 1:
The patent uses the TAT-BH4 peptide as an intermediary substance that mediates between the administered drug and the target astrocytes. The peptide specifically targets and modulates intracellular calcium signaling in astrocytes, thereby protecting them from degeneration without requiring direct administration of complex molecules. This intermediary approach enables effective treatment of astrocyte degeneration while maintaining ease of administration.
2Reliability
If the TAT-BH4 peptide is administered to modulate intracellular calcium signaling, then astrocyte protection and cell survival are improved, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent extracts the critical protective function from the complex Bcl-XL protein by isolating and utilizing only the BH4 domain, which is responsible for modulating intracellular calcium signaling. This extraction simplifies the treatment mechanism by using a smaller, more manageable peptide (TAT-BH4) that retains the essential protective function while reducing the complexity associated with administering and delivering the full-length protein.
3Duration of action of stationary object
If astrocyte degeneration is allowed to progress, then the natural disease course occurs, but the microenvironment essential for motor neuron function deteriorates
Solution Approach 1:
The patent applies preliminary action by administering the TAT-BH4 peptide before significant astrocyte degeneration occurs or at the early stages of ALS. This preventive approach modulates intracellular calcium signaling in astrocytes to protect them from degeneration, thereby preserving the microenvironment quality for motor neurons before it deteriorates. The peptide is delivered systemically and accumulates in the central nervous system where it exerts its protective effect on astrocytes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TAT-BH4 peptide restores normal calcium oscillations in astrocytes, reduces astrocyte degeneration, delays disease onset, improves motor performance, and extends lifespan in ALS transgenic mice by providing glioprotective effects and promoting cell survival.
Implementation Method 1
The BH4 domain of Bcl-XL rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals
Data Source
AI summary
The described invention relates to the use of the TAT-BH4 peptide for treating or preventing the progression of ALS. The methods include, postponing the appearance of symptoms and improving motor performance and survival in ALS. Methods are also provided, wherein the TAT-BH4 peptide is in a composition further comprising a pharmaceutically acceptable excipient.